Journals / Klinik Tıp Aile Hekimliği / 2017 / Cilt: 9 - Sayı: 4

Topical NSAIDs in the Treatment of Osteoarthritis

Osteoartrit Tedavisinde Topikal NSAİİ’lerin Yeri

Pages
6–11
Publication Date
2017-07-26
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, as manyas 40% of those aged over 65 in the community may have symptomatic OA.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Abstract Osteoarthritis, the most common chronic disease in the joints, resulting destruction.It is the most common cause of pain and loss of function in society.
📊
Key Findings & Data:Overall, as manyas 40% of those aged over 65 in the community may have symptomatic OA.
💡
Conclusion & Impact:In this review, current effectivneess of topical NSAİDs’ will be discussed in osteoarthritis.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Osteoarthritis · topikal nonsteroid antiinflamatuar ilaçlar · tedavi klavuzları

Abstract

Abstract Osteoarthritis, the most common chronic disease in the joints, resulting destruction.It is the most common cause of pain and loss of function in society. Overall, as manyas 40% of those aged over 65 in the community may have symptomatic OA. The aimsof the treatment in OA are reducing joint pain and stiffness, maintaining and improvingjoint mobility, reducing physical disability and handicap, improving health related quality of life, limiting the progression of joint damage and educating patients about the nature of the disorder and its progression. The recommended pharmacological modalities include acetaminophen, non-steroidal anti-inflammatory drugs, drugs and capsaicin,intraarticular injections of corticosteroids and hyaluronates, symptomatic slow acting drugsfor osteoarthritis and opioid analgesics. In this review, current effectivneess of topical NSAİDs’ will be discussed in osteoarthritis.

Özet

ÖzOsteoartrit (OA), eklemlerde en sık rastlanan, destruksiyonla sonuçlanan kronik birhastalıktır. Eklemlerdeki ağrı ve fonksiyon kaybının toplumdaki en sık nedenidir. Genel olarak toplumda 65 yaş üzeri bireylerde semptomatik OA %40’a varan oranlarda görülebilir. OA’da tedavinin amaçları eklem ağrısı ve tutukluğunu azaltmak, eklem mobilitesini korumak ve iyileştirmek, fiziksel kısıtlılıkları ve engelliliği azaltmak, yaşam ka-litesini arttırmak, eklem hasarının ilerlemesini önlemek ve hastalığın seyri ve sonuçları konusunda hastayı eğitmektir. Önerilen farmakolojik modaliteler ise asetaminofen, nonsteroid antiinflamatuvar ilaçlar, topikal antiinflamatuvar ilaçlar ve kapsaisin, intraartiküler kortikosteroid ve hiyalüronatlar, semptomatik yavaş etkili OA ilaçları ve opioid analjezikleri içerir. Bu derlemede OA li hastalarda topikal NSAİ ilaçların etkinliği üzerinde duracağız

🔖

Cite This Article

LÜLECİ, P. D. N. E. (2017). Topical NSAIDs in the Treatment of Osteoarthritis. Klinik Tıp Aile Hekimliği, Cilt: 9 - Sayı: 4, 6–11. https://ajindex.com/articles/838130

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kaynaklar 1. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT,Giannini EH, et al. Estimates of the prevalence of arthritis andselected musculoskeletal _disorders in the United States. Arth-ritis Rheum 1998;41:778-99.2. Mow VC, Setton LA, Fuilak F, Ratcliffe A. Mechanical fac-tors in articular cartilage and their role in osteoarthritis. In:Kuettner KE, RECOMMENDATIONS FOR HIP AND KNEEOA MANAGEMENT Goldberg VM, editors. Osteoarthritic di-sorders. Rosemont (IL): American Academy of OrthopaedicSurgeons; 1995. p. 147-72.3. Poole AR. Imbalances of anabolism and catabolism of carti-lage matrix components in osteoarthritis. In:Kuettner KE, Gold-berg VM, editors. Osteoarthritic disorders. Rosemont (IL): Ame-rican Academy of Orthopaedic Surgeons; 1995. p. 247-60.4. Holderbaum D, Haqqi TM, Moskowitz RW. Genetics and os-teo arthritis: exposing the iceberg. Arthritis Rheum1999;42:397-405.5. Dieppe PA: Osteoarthritis and related disorder. In: Rheuma-tology (Eds. Klippel JH, Dieppe PA). Mosby, London, 1998,pp1.1–12.16.6. Zhang W, Doherty M, Peat G, et al. EULAR evidencebasedrecommendations for the diagnosis of knee osteoarthritis. AnnRheum Dis 2010;69:483-9.7. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA,Griffin MR, et al. Guidelines for the medical management ofosteoarthritis. Part 1. Osteoarthritis of the hip. Arthritis Rhe-um 1995;38:1535-40.8. Hochberg MC, Altman RD, Brandt KD, Clark BM, Dieppe PA,Griffin MR, et al. Guidelines for the medical management ofosteoarthritis. Part II. Osteoarthritis of the knee. Arthritis Rhe-um 1995;38:1541-6.9. Towheed TE, Hochberg MC. A systematic review of randomi-zed controlled trials of pharmacological therapy in patientswith osteoarthritis of the hip. J Rheumatol 1997;24:349-57.10. Towheed TE, Hochberg MC. A systematic review of rando-mized controlled trials of pharmacological therapy in patientswith osteoarthritis of the knee. Semin Arthritis Rheum1997;27:755-70.11. Watson MC, Brookes ST, Kirwan JR, Faulkner A. Non-aspi-rin, non-steroidal anti-inflammatory drugs for osteoarthritisof the knee (Cochrane review). In: The Cochrane library, is-sue 1. Ox ford: Update Software; 2000. Accessed April 11, 200012. Towheed T, Shea B, Wells G, Hochberg M. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoar thri-tis of the hip (Cochrane review). In: The Cochrane library, is-sue 1. Oxford: Update Software; 2000. Accessed April 11, 2000.13. Gotzsche PC. Non-steroidal anti-inflammatory drugs. BMJ2000; 320:1